The United States Patent and Trademark Office (USPTO) has granted patent US12583870B2, covering an azaheteroaryl compound, its pharmaceutically acceptable salts, solvates, and methods of preparation. The patent, assigned to SHANGHAI BLUERAY BIOPHARMA CO., LTD., specifically relates to compounds useful in the preparation of drugs targeting diseases or disorders associated with the mechanism of action of EED protein and/or PRC2 protein complex.

This patent grant signifies new intellectual property protection for the assignee in the field of pharmaceutical development. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on other entities, it is relevant for drug manufacturers and pharmaceutical companies operating in this therapeutic area. Companies should be aware of this granted patent to ensure their own research, development, and commercialization activities do not infringe upon the patent's claims, particularly concerning compounds targeting EED protein and PRC2 protein complex pathways.